IL115875A - Methods of inhibiting pneumocystis carinii pneumonia giardia lamblia and cryptosporidium parvum in an animal subject and compounds useful therefor - Google Patents

Methods of inhibiting pneumocystis carinii pneumonia giardia lamblia and cryptosporidium parvum in an animal subject and compounds useful therefor

Info

Publication number
IL115875A
IL115875A IL11587595A IL11587595A IL115875A IL 115875 A IL115875 A IL 115875A IL 11587595 A IL11587595 A IL 11587595A IL 11587595 A IL11587595 A IL 11587595A IL 115875 A IL115875 A IL 115875A
Authority
IL
Israel
Prior art keywords
inhibiting
methods
compounds useful
animal subject
pneumocystis carinii
Prior art date
Application number
IL11587595A
Other languages
English (en)
Other versions
IL115875A0 (en
Original Assignee
Univ Georgia State Res Found
Univ North Carolina
Univ Auburn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia State Res Found, Univ North Carolina, Univ Auburn filed Critical Univ Georgia State Res Found
Publication of IL115875A0 publication Critical patent/IL115875A0/xx
Publication of IL115875A publication Critical patent/IL115875A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
IL11587595A 1994-11-14 1995-11-05 Methods of inhibiting pneumocystis carinii pneumonia giardia lamblia and cryptosporidium parvum in an animal subject and compounds useful therefor IL115875A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33948794A 1994-11-14 1994-11-14

Publications (2)

Publication Number Publication Date
IL115875A0 IL115875A0 (en) 1996-01-31
IL115875A true IL115875A (en) 2000-12-06

Family

ID=23329224

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11587595A IL115875A (en) 1994-11-14 1995-11-05 Methods of inhibiting pneumocystis carinii pneumonia giardia lamblia and cryptosporidium parvum in an animal subject and compounds useful therefor

Country Status (11)

Country Link
EP (1) EP0792271B1 (xx)
JP (1) JP4023753B2 (xx)
AR (1) AR003104A1 (xx)
AT (1) ATE213737T1 (xx)
AU (1) AU692024B2 (xx)
CA (1) CA2204898A1 (xx)
DE (1) DE69525644T2 (xx)
ES (1) ES2173988T3 (xx)
IL (1) IL115875A (xx)
WO (1) WO1996015126A1 (xx)
ZA (1) ZA959661B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6008247A (en) * 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
WO2000010990A2 (en) * 1998-08-20 2000-03-02 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
EP1013649A1 (en) * 1998-12-22 2000-06-28 Chisso Corporation Liquid crystal compounds incorporating furan ring, liquid crystal composition and liquid crystal display device
GB2351081A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
US7163955B2 (en) 2001-01-13 2007-01-16 The University Of North Carolina At Chapel Hill Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection
JP2006508164A (ja) * 2002-11-27 2006-03-09 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗原生動物剤としての二価陽イオン性２，５−ジアリールフランアザ−アナログ
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20090298934A1 (en) * 2006-03-27 2009-12-03 Government Of The Us, As Represented By The Secret Diamidine Inhibitors of TDP1

Also Published As

Publication number Publication date
DE69525644D1 (de) 2002-04-04
JPH10508857A (ja) 1998-09-02
ATE213737T1 (de) 2002-03-15
WO1996015126A1 (en) 1996-05-23
MX9703611A (es) 1998-07-31
ES2173988T3 (es) 2002-11-01
DE69525644T2 (de) 2002-10-17
IL115875A0 (en) 1996-01-31
AU4283896A (en) 1996-06-06
CA2204898A1 (en) 1996-05-23
ZA959661B (en) 1996-05-29
EP0792271B1 (en) 2002-02-27
EP0792271A1 (en) 1997-09-03
AR003104A1 (es) 1998-07-08
AU692024B2 (en) 1998-05-28
JP4023753B2 (ja) 2007-12-19

Similar Documents

Publication Publication Date Title
DE59405534D1 (de) Probenträger und seine verwendung
PL332957A1 (en) Method of obtaining nanoparticles of methylidene malonate possibly those containing one or several type of biologically active particles
SG65705A1 (en) 3-Hydroxypiridine-2-carboxamidoesters their perparation and their use as pharmaceuticals
DE69504327T2 (de) Chemisch modifizierte festphase-extraktionspartikel und diese enthaltende artikel
HU9302829D0 (en) Plant kitinase gene and its application
IL113308A0 (en) Fertilizer suspension and its preparation
DE69314280D1 (de) Rekombinantes Nitrilase und deren Verwendung
IL115875A (en) Methods of inhibiting pneumocystis carinii pneumonia giardia lamblia and cryptosporidium parvum in an animal subject and compounds useful therefor
PL296034A2 (en) Composition exibiting-fgf activity and method of obtaining same
DE59401465D1 (de) Pulverlack und seine Verwendung
SG45142A1 (en) Improved fumigation of particulate commodities
DE69811165D1 (de) Heparin-spezifische Glucanase-enthaltende Additivzubereitung und seine Verwendung
DE59307396D1 (de) Dichtring und verwendung desselben
DE69812256T2 (de) 7-Propylbenzodioxepin-3-one und seine Verwendung in der Parfümerie
DE69530446D1 (de) Ozonisator und seine Verwendung
EP0558178A3 (en) Permeable magnetic composition and magnetic component
DE69327926D1 (de) Magnetisches Teilchen und seine Verwendung in einem Immunotest
DE69315906T2 (de) Vorrichtung zur Videosignal-Umwandlung und Rauschunterdrückung
GB2268422B (en) Dewatering of suspensions and polyners for use in this
DE69416733D1 (de) Bilderzeugungsgerät und seine Verwendung
PL341396A1 (en) Modified syntheses of diacetoxycephalosporin c (daocs) and its roentgenographic structure
GB9621821D0 (en) Processing and use of particulate materials
ZA925263B (en) Modulation and diagnosis of cytokine dysfunctions
GB9222906D0 (en) Amplitude limiting amplifier and method of amplitude limiting
PL296278A1 (en) Novel ruthene catalyst and method of obtaining same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees